Nucala Drug Information

Generic name: MEPOLIZUMAB

Interleukin-5 Antagonist [EPC]

Save on Nucala at your pharmacy Compare prices near you and start saving today—no enrollment required.
See Prices

Uses of Nucala

  • is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for:
  • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 )
  • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 )
  • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 )
  • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 )
  • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations ( 8.4 ), Clinical Studies ( 14.1 )] . Limitations of Use NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . 1.2 Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids. 1.3 Maintenance Treatment of Chronic Obstructive Pulmonary Disease NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Limitations of Use NUCALA is not indicated for the relief of acute bronchospasm [see Warnings and Precautions ( 5.2 )]. 1.4 Eosinophilic Granulomatosis with Polyangiitis NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1.5 Hypereosinophilic Syndrome NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause.

Dosage & Administration of Nucala

a 300 mg dose is administered as 3 separate 100 mg dose injections administered at least 5 cm (approximately 2 inches) apart.
IndicationAdults
Severe asthma100 mg every 4 weeks
Chronic rhinosinusitis with nasal polyps100 mg every 4 weeks
Chronic obstructive pulmonary disease100 mg every 4 weeks
Eosinophilic granulomatosis with polyangiitis300 mga every 4 weeks
Hypereosinophilic syndrome300 mga every 4 weeks

Side Effects of Nucala

  • The following adverse reactions are described in greater detail in other sections:
  • Hypersensitivity reactions [see Warnings and Precautions ( 5.1 )]
  • Opportunistic infections: herpes zoster [see Warnings and Precautions ( 5.3 )] Most common adverse reactions (incidence ≥5%):
  • Asthma: Headache, injection site reaction, back pain, and fatigue. ( 6.1 )
  • CRSwNP: Oropharyngeal pain and arthralgia. ( 6.1 )
  • COPD: Back pain, diarrhea, and cough. ( 6.1 )
  • EGPA and HES: Most common adverse reactions are similar to asthma. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Adult and Adolescent Patients Aged 12 Years and Older with Severe Asthma A total of 1,327 patients with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks’ duration (Severe Asthma Trials DREAM, MENSA, and SIRIUS). Of these, 1,192 had a history of 2 or more exacerbations in the year prior to enrollment despite regular use of high-dose ICS plus additional controller(s) (Severe Asthma Trials DREAM and MENSA), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control (Severe Asthma Trial SIRIUS). All patients had markers of eosinophilic airway inflammation [see Clinical Studies ( 14.1 )] . Of the patients enrolled, 59% were female, 85% were White, and ages ranged from 12 to 82 years. Mepolizumab was administered subcutaneously or intravenously once every 4 weeks; 263 patients received NUCALA (mepolizumab 100 mg subcutaneously) for at least 24 weeks. Serious adverse events that occurred in more than 1 patient and in a greater percentage of patients receiving NUCALA 100 mg (n = 263) than placebo (n = 257) included 1 event, herpes zoster (2 patients vs. 0 patients, respectively). The incidence of adverse reactions in the first 24 weeks of treatment in the 2 confirmatory efficacy and safety trials MENSA and SIRIUS with NUCALA 100 mg is shown in Table 2 . Table 2. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with Severe Asthma (MENSA and SIRIUS) Adverse Reaction NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 263) % Placebo (n = 257) % Headache 19 18 Injection site reaction 8 3 Back pain 5 4 Fatigue 5 4 Influenza 3 2 Urinary tract infection 3 2 Abdominal pain upper 3 2 Pruritus 3 2 Eczema 3 <1 Muscle spasms 3 <1 52-Week Trial: Adverse reactions from the Severe Asthma Trial DREAM with 52 weeks of treatment with mepolizumab 75 mg intravenously (n = 153) or placebo (n = 155) and with ≥3% incidence and more common than placebo and not shown in Table 2 were: abdominal pain, allergic rhinitis, asthenia, bronchitis, cystitis, dizziness, dyspnea, ear infection, gastroenteritis, lower respiratory tract infection, musculoskeletal pain, nasal congestion, nasopharyngitis, nausea, pharyngitis, pyrexia, rash, toothache, viral infection, viral respiratory tract infection, and vomiting. In addition, 3 cases of herpes zoster occurred in patients receiving mepolizumab 75 mg intravenously compared with 2 patients in the placebo group. Systemic Reactions, including Hypersensitivity Reactions: In the Severe Asthma Trials DREAM, MENSA, and SIRIUS described above, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100 mg and 5% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients in the group receiving NUCALA 100 mg and 2% of patients in the placebo group. The most commonly reported manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving NUCALA 100 mg included rash, pruritus, headache, and myalgia. Systemic non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100 mg and 3% of patients in the placebo group. The most commonly reported manifestations of systemic non‑allergic reactions reported in the group receiving NUCALA 100 mg included rash, flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 100 mg (5/7) were experienced on the day of dosing. Injection Site Reactions: Injection site reactions (e.g., pain, erythema, swelling, itching, burning sensation) occurred at a rate of 8% in patients receiving NUCALA 100 mg compared with 3% in patients receiving placebo. Long-Term Safety: Nine hundred ninety-eight patients received NUCALA 100 mg in open-label extension studies, during which additional cases of herpes zoster were reported. The overall adverse event profile has been similar to the severe asthma trials described above. Adverse Reactions in Pediatric Patients Aged 6 to 11 Years with Severe Asthma The safety data for NUCALA is based upon 1 open-label clinical trial that enrolled 36 patients with severe asthma aged 6 to 11 years. Patients received 40 mg (for those weighing <40 kg) or 100 mg (for those weighing ≥40 kg) of NUCALA administered subcutaneously once every 4 weeks. Patients received NUCALA for 12 weeks (initial short phase). After a treatment interruption of 8 weeks, 30 patients received NUCALA for a further 52 weeks (long phase). The adverse reaction profile for patients aged 6 to 11 years was similar to that observed in patients aged 12 years and older. Adverse Reactions in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps A total of 407 patients with CRSwNP were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received NUCALA 100 mg or placebo subcutaneously once every 4 weeks. Patients had recurrent CRSwNP with a history of prior surgery and were on nasal corticosteroids for at least 8 weeks prior to screening [see Clinical Studies ( 14.2 )] . Of the patients enrolled, 35% were female, 93% were White, and ages ranged from 18 to 82 years. Table 3 summarizes adverse reactions that occurred in ≥3% of patients treated with NUCALA and more frequently than in patients treated with placebo in the CRSwNP trial. Table 3. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with Chronic Rhinosinusitis with Nasal Polyps Adverse Reaction NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 206) % Placebo (n = 201) % Oropharyngeal pain 8 5 Arthralgia 6 2 Abdominal pain upper 3 2 Diarrhea 3 2 Pyrexia 3 2 Nasal dryness 3 <1 Rash 3 <1 Systemic Reactions, including Hypersensitivity Reactions: In the 52-week trial, the percentage of patients who experienced systemic (allergic [type I hypersensitivity] and other) reactions was <1% in the group receiving NUCALA 100 mg and <1% in the placebo group. Systemic allergic (type I hypersensitivity) reactions were reported by <1% of patients in the group receiving NUCALA 100 mg and no patients in the placebo group. The manifestations of systemic allergic (type I hypersensitivity) reactions included urticaria, erythema, and rash and 1 of the 3 reactions occurred on the day of dosing. Other systemic reactions were reported by no patients in the group receiving NUCALA 100 mg and <1% of patients in the placebo group. Injection Site Reactions: Injection site reactions (e.g., erythema, pruritus) occurred at a rate of 2% in patients receiving NUCALA 100 mg compared with <1% in patients receiving placebo. Adverse Reactions in Adults with Chronic Obstructive Pulmonary Disease The safety data below reflects the safety of NUCALA in adults with inadequately controlled COPD and an eosinophilic phenotype. NUCALA was evaluated in a pooled safety population that consisted of 2089 patients with COPD in 3 randomized, placebo-controlled, multicenter trials of 52 to 104 weeks duration, including MATINEE and METREX [see Clinical Studies ( 14.3 )] , and Trial 3. Trial 3 enrolled COPD adults with a peripheral blood eosinophil count ≥150 cells/µL at screening or ≥300 cells/µL in the year prior. The pooled safety population received NUCALA 100 mg (n = 1043) or placebo (n = 1046), administered subcutaneously once every 4 weeks, in addition to background triple inhaled therapies (e.g., ICS, long-acting beta agonist [LABA], and long-acting muscarinic antagonist [LAMA]). Table 4 summarizes adverse reactions that occurred in ≥3% of patients treated with NUCALA and more frequently than in patients treated with placebo in COPD trials. Table 4. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with Chronic Obstructive Pulmonary Disease in a Pooled Safety Population (MATINEE, METREX, and Trial 3) Adverse Reaction NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 1043) % Placebo (n = 1046) % Back pain 7 6 Diarrhea 5 4 Cough 5 4 Oropharyngeal pain 4 2 Urinary tract infection 4 3 Pain in extremity 4 3 Herpes Zoster: In the pooled safety population, 14 (1%) patients in the NUCALA group compared to 7 (0.7%) patients in the placebo group experienced herpes zoster. Adverse Reactions in Patients with Eosinophilic Granulomatosis with Polyangiitis A total of 136 patients with EGPA were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients enrolled had a diagnosis of EGPA for at least 6 months prior to enrollment with a history of relapsing or refractory disease and were on a stable dosage of oral prednisolone or prednisone of greater than or equal to 7.5 mg/day (but not greater than 50 mg/day) for at least 4 weeks prior to enrollment [see Clinical Studies ( 14.4 )] . Of the patients enrolled, 59% were female, 92% were White, and ages ranged from 20 to 71 years. No additional adverse reactions were identified to those reported in the severe asthma trials. Systemic Reactions, including Hypersensitivity Reactions: In the 52-week trial, the percentage of patients who experienced systemic (allergic and non‑allergic) reactions was 6% in the group receiving 300 mg of NUCALA and 1% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 4% of patients in the group receiving 300 mg of NUCALA and 1% of patients in the placebo group. The manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving 300 mg of NUCALA included rash, pruritus, flushing, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, and stridor. Systemic non-allergic reactions were reported by 1 (1%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of systemic non-allergic reactions reported in the group receiving 300 mg of NUCALA was angioedema. Half of the systemic reactions in patients receiving 300 mg of NUCALA (2/4) were experienced on the day of dosing. Injection Site Reactions: Injection site reactions (e.g., pain, erythema, swelling) occurred at a rate of 15% in patients receiving 300 mg of NUCALA compared with 13% in patients receiving placebo. Adverse Reactions in Adult and Adolescent Patients with Hypereosinophilic Syndrome A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo‑controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1‑PDGFRα kinase-positive HES were excluded from the trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients must have been on a stable dose of background HES therapy for the 4 weeks prior to randomization [see Clinical Studies ( 14.5 )] . Of the patients enrolled, 53% were female, 93% were White, and ages ranged from 12 to 82 years. No additional adverse reactions were identified to those reported in the severe asthma trials. Systemic Reactions, including Hypersensitivity Reactions: In the trial, no systemic allergic (type I hypersensitivity) reactions were reported. Other systemic reactions were reported by 1 (2%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of other systemic reaction was multifocal skin reaction experienced on the day of dosing. Injection Site Reactions: Injection site reactions (e.g., burning, itching) occurred at a rate of 7% in patients receiving 300 mg of NUCALA compared with 4% in patients receiving placebo. 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during post-approval use of NUCALA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to NUCALA or a combination of these factors. Immune System Disorders Hypersensitivity reactions, including anaphylaxis.

Warnings & Cautions for Nucala

  • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. Discontinue NUCALA in the event of a hypersensitivity reaction. ( 5.1 )
  • Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate. ( 5.3 )
  • Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decrease corticosteroids gradually, if appropriate. ( 5.4 )
  • Treat patients with pre-existing helminth infections before therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until parasitic infection resolves. ( 5.5 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances can have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, NUCALA should be discontinued [see Contraindications ( 4 )] . 5.2 Acute Symptoms of Asthma or Chronic Obstructive Pulmonary Disease or Acute Deteriorating Disease NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD. Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma or COPD remains uncontrolled or worsens after initiation of treatment with NUCALA. 5.3 Opportunistic Infections: Herpes Zoster Herpes zoster has occurred in subjects receiving NUCALA 100 mg in controlled clinical trials [see Adverse Reactions ( 6.1 )] . Consider vaccination if medically appropriate. 5.4 Reduction of Corticosteroid Dosage Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of therapy with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. 5.5 Parasitic (Helminth) Infection Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient’s response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.

Drug Interactions with Nucala

Formal drug interaction trials have not been performed with NUCALA.

Pregnancy Safety for Nucala

Pregnancy Risk Summary The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. In a prenatal and postnatal development study conducted in cynomolgus monkeys, there was no evidence of fetal harm with intravenous administration of mepolizumab throughout pregnancy at doses that produced exposures up to approximately 9 times the exposure at the maximum recommended human dose (MRHD) of 300 mg subcutaneous (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control. Data Animal Data: In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation Days 20 to 140 at doses that produced exposures up to approximately 9 times that achieved with the MRHD (on an AUC basis with maternal intravenous doses up to 100 mg/kg once every 4 weeks). Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth.

Examinations for internal or skeletal malformations were not performed. Mepolizumab crossed the placenta in cynomolgus monkeys. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers up to Day 178 postpartum.

Levels of mepolizumab in milk were ≤0.5% of maternal serum concentration. In a fertility, early embryonic, and embryofetal development study, pregnant CD-1 mice received an analogous antibody, which inhibits the activity of murine interleukin-5 (IL-5), at an intravenous dose of 50 mg/kg once per week throughout gestation. The analogous antibody was not teratogenic in mice.

Embryofetal development of IL-5–deficient mice has been reported to be generally unaffected relative to wild-type mice.

Pediatric Use of Nucala

Pediatric Use Severe Asthma The safety and effectiveness of NUCALA for severe asthma, and with an eosinophilic phenotype, have been established in pediatric patients aged 6 years and older. Use of NUCALA in adolescents aged 12 to 17 years is supported by evidence from adequate and well-controlled trials in adults and adolescents. A total of 28 adolescents aged 12 to 17 years with severe asthma were enrolled in the Phase 3 asthma trials.

Of these, 25 were enrolled in the 32-week exacerbation trial (MENSA) and had a mean age of 14.8 years. Patients had a history of 2 or more exacerbations in the previous year despite regular use of medium- or high-dose ICS plus additional controller(s) with or without OCS and had blood eosinophils of ≥150 cells/mcL at screening or ≥300 cells/mcL within 12 months prior to enrollment. Patients had a reduction in the rate of exacerbations that trended in favor of NUCALA. Of the 19 adolescents who received NUCALA, 9 received 100 mg and the mean apparent clearance in these patients was 35% less than that of adults.

The safety profile observed in adolescents was generally similar to that of the overall population in the Phase 3 studies . Use of NUCALA in pediatric patients aged 6 to 11 years with severe asthma, and with an eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in children aged 6 to 11 years. A single open-label clinical trial was conducted in 36 children aged 6 to 11 years (mean age: 8.6 years, 31% female) with severe asthma. Enrollment criteria were the same as for adolescents in the 32-week exacerbation trial (MENSA). Based upon the pharmacokinetic data from this trial, a subcutaneous dose of 40 mg every 4 weeks was determined to have similar exposure to adults and adolescents administered a subcutaneous dose of 100 mg . The effectiveness of NUCALA in pediatric patients aged 6 to 11 years is extrapolated from efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar drug exposure levels for 40 mg administered subcutaneously every 4 weeks in children aged 6 to 11 years compared with adults and adolescents . The safety profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were similar to that seen in adults and adolescents . The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma have not been established.

Chronic Rhinosinusitis with Nasal Polyps The safety and effectiveness in patients aged younger than 18 years with CRSwNP have not been established. Chronic Obstructive Pulmonary Disease The safety and effectiveness in pediatric patients aged younger than 18 years with COPD have not been established. COPD is largely a disease of adult patients.

Eosinophilic Granulomatosis with Polyangiitis The safety and effectiveness in patients aged younger than 18 years with EGPA have not been established. Hypereosinophilic Syndrome The safety and effectiveness of NUCALA for HES have been established in adolescent patients aged 12 years and older. The safety and effectiveness in pediatric patients aged younger than 12 years with HES have not been established.

Use of NUCALA for this indication is supported by evidence from an adequate and well-controlled study (NCT02836496) in adults and adolescents and an open-label extension study (NCT03306043). One adolescent received NUCALA during the controlled study and this patient and an additional 3 adolescents received NUCALA during the open-label extension study . The 1 adolescent treated with NUCALA in the 32-week trial did not have a HES flare or an adverse event reported. All adolescents received 300 mg of NUCALA for 20 weeks in the open-label extension.

Contraindications for Nucala

is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation . History of hypersensitivity to mepolizumab or excipients in the formulation.

Overdosage Information for Nucala

There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

Clinical Studies of Nucala

Severe Asthma

The asthma development program for NUCALA in patients aged 12 years and older included 3 double-blind, randomized, placebo‑controlled trials: 1 dose-ranging and exacerbation trial (DREAM, NCT01000506) and 2 confirmatory trials (MENSA, NCT01691521 and SIRIUS, NCT01691508). Mepolizumab was administered every 4 weeks in all 3 trials as add-on to background treatment. All patients continued their background asthma therapy throughout the duration of the trials. Dose-Ranging and Exacerbation Trial DREAM was a 52-week dose-ranging and exacerbation-reduction trial in patients with severe asthma with a history of 2 or more exacerbations in the previous year despite regular use of high‑dose ICS plus additional controller(s) with or without OCS. Patients enrolled in this trial were required to have at least 1 of the following 4 pre-specified criteria in the previous 12 months: blood eosinophil count ≥300 cells/mcL, sputum eosinophil count ≥3%, exhaled nitric oxide concentration ≥50 ppb, or deterioration of asthma control after ≤25% reduction in regular maintenance ICS/OCS. Three intravenous dosages of mepolizumab (75, 250, and 750 mg) administered once every 4 weeks were evaluated compared with placebo.

Results from this trial and the pharmacodynamic study supported the evaluation of mepolizumab 75 mg intravenously and 100 mg subcutaneously in the subsequent trials . NUCALA is not indicated for intravenous use and should only be administered by the subcutaneous route. Confirmatory Trials A total of 711 patients with severe asthma were studied in the 2 confirmatory trials (MENSA and SIRIUS). In these 2 trials patients were required to have blood eosinophils of ≥150 cells/mcL at screening (within 6 weeks of dosing) or blood eosinophils of ≥300 cells/mcL within 12 months of enrollment. The screening blood eosinophils of ≥150 cells/mcL criterion was derived from exploratory analyses of data from the DREAM Trial.

MENSA was a 32-week placebo‑ and active‑controlled trial in patients with severe asthma with a history of 2 or more exacerbations in the previous year despite regular use of high-dose ICS plus additional controller(s) with or without OCS. Patients received mepolizumab 75 mg intravenously (n = 191), NUCALA 100 mg (n = 194), or placebo (n = 191) once every 4 weeks for 32 weeks. SIRIUS was a 24-week OCS-reduction trial in patients with severe asthma who required daily OCS in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control. Patients in the SIRIUS Trial were not required to have a history of exacerbations in the previous year.

Patients received NUCALA 100 mg (n = 69) or placebo (n = 66) once every 4 weeks for 24 weeks. The baseline mean OCS use was similar in the 2 treatment groups: 13.2 mg in the placebo group and 12.4 mg in the group receiving NUCALA 100 mg. The demographics and baseline characteristics of these 3 trials are provided in Table 5. Table 5. Demographics and Baseline Characteristics of Severe Asthma Trials FEV 1 = forced expiratory volume in 1 second, SABA = short-acting beta 2 -agonist, FVC = forced vital capacity.

DREAM (N = 616) MENSA (N = 576) SIRIUS (N = 135) Mean age, years 49 50 50 Female, n (%) 387 328 74 White, n (%) 554 450 128 Duration of asthma, years, mean 19 20 19 Never smoked, n (%) 483 417 82 Baseline FEV 1, L 1.88 1.82 1.95 Baseline % predicted FEV 1 60 61 59 Baseline % reversibility 25 27 26 Baseline post-SABA FEV 1 /FVC 0.67 0.66 0.66 Geometric mean eosinophil count at baseline, cells/mcL 250 290 240 Mean number of exacerbations in previous year 3.6 3.6

Exacerbations Efficacy was assessed in

DREAM and MENSA using an endpoint of the frequency of exacerbations defined as worsening of asthma requiring use of oral/systemic corticosteroids and/or hospitalization and/or emergency department visits. For patients on maintenance OCS, an exacerbation requiring OCS was defined as the use of oral/systemic corticosteroids at least double the existing dose for at least 3 days. Compared with placebo, patients receiving NUCALA 100 mg or mepolizumab 75 mg intravenously experienced significantly fewer exacerbations.

Additionally, compared with placebo, there were fewer exacerbations requiring hospitalization and/or emergency department visits and exacerbations requiring only in-patient hospitalization with NUCALA 100 mg ( Table 6 ). Table 6. Rate of Exacerbations in Severe Asthma Trials DREAM and MENSA (Intent-to-Treat Population) CI = confidence interval, IV = intravenous, SC = subcutaneous. Trial Treatment Exacerbations per Year Rate Difference Rate Ratio (95% CI) All exacerbations DREAM Placebo (n = 155) 2.40 Mepolizumab 75 mg IV (n = 153) 1.24 1.16 0.52 MENSA Placebo (n = 191) 1.74 Mepolizumab 75 mg IV (n = 191) 0.93 0.81 0.53 NUCALA 100 mg SC (n = 194) 0.83 0.91 0.47 Exacerbations requiring hospitalization/emergency room visit DREAM Placebo (n = 155) 0.43 Mepolizumab 75 mg IV (n = 153) 0.17 0.26 0.40 MENSA Placebo (n = 191) 0.20 Mepolizumab 75 mg IV (n = 191) 0.14 0.06 0.68 NUCALA 100 mg SC (n = 194) 0.08 0.12 0.39 Exacerbations requiring hospitalization DREAM Placebo (n = 155) 0.18 Mepolizumab 75 mg IV (n = 153) 0.11 0.07 0.61 MENSA Placebo (n = 191) 0.10 Mepolizumab 75 mg IV (n = 191) 0.06 0.04 0.61 NUCALA 100 mg SC (n = 194) 0.03 0.07 0.31 The time to first exacerbation was longer for the groups receiving NUCALA 100 mg and mepolizumab 75 mg intravenously compared with placebo in MENSA ( Figure 1 ). Figure 1. Kaplan-Meier Cumulative Incidence Curve for Time to First Exacerbation (MENSA) IV = intravenous, SC = subcutaneous. DREAM data were explored to determine criteria that could identify patients likely to benefit from treatment with NUCALA. The exploratory analysis suggested that baseline blood eosinophil count of ≥150 cells/mcL was a potential predictor of treatment benefit.

Exploratory analysis of MENSA data also suggested that baseline blood eosinophil count (obtained within 6 weeks of initiation of dosing) of ≥150 cells/mcL was a potential predictor of efficacy and showed a trend of greater exacerbation benefit with increasing blood eosinophil count. In MENSA, patients enrolled solely on the basis of the historical blood eosinophil count of ≥300 cells/mcL in the previous 12 months, but who had a baseline blood eosinophil count <150 cells/mcL, had virtually no exacerbation benefit following treatment with NUCALA 100 mg compared with placebo. The Asthma Control Questionnaire-5 (ACQ-5) was assessed in Trials DREAM and MENSA, and the St.

George’s Respiratory Questionnaire (SGRQ) was assessed in MENSA. In DREAM, the ACQ-5 responder rate (defined as a decrease in score of 0.5 or more as threshold) for the 75-mg intravenous mepolizumab arm was 47% compared with 50% for placebo with an odds ratio (OR) of 1.1 (95% confidence interval : 0.7, 1.7). In MENSA, the ACQ-5 responder rate for the treatment arm for NUCALA 100 mg was 57% compared with 45% for placebo with an OR of 1.8 (95% CI: 1.2, 2.8). In MENSA, the SGRQ responder rate (defined as a decrease in score of 4 or more as threshold) for the treatment arm for NUCALA 100 mg was 71% compared with 55% for placebo with an OR of 2.1 (95% CI: 1.3, 3.2). Oral Corticosteroid Reduction Severe Asthma Trial SIRIUS evaluated the effect of NUCALA 100 mg on reducing the use of maintenance OCS. Efficacy was assessed using an endpoint of the percent reduction of OCS dose during Weeks 20 to 24 compared with baseline dose, while maintaining asthma control. Patients were classified according to their change in OCS use during the trial with the following categories: 90% to 100% decrease, 75% to <90% decrease, 50% to <75% decrease, >0% to <50% decrease, and no improvement (i.e., no change or any increase or lack of asthma control or withdrawal of treatment). Compared with placebo, patients receiving NUCALA 100 mg achieved greater reductions in daily maintenance OCS dose, while maintaining asthma control. Sixteen (23%) patients in the group receiving NUCALA 100 mg versus 7 (11%) in the placebo group had a 90% to 100% reduction in their OCS dose.

Twenty-five (36%) patients in the group receiving NUCALA 100 mg versus 37 (56%) in the placebo group were classified as having no improvement for OCS dose. Additionally, 54% of patients receiving NUCALA 100 mg achieved at least a 50% reduction in the daily prednisone dose compared with 33% of patients receiving placebo (95% CI for difference: 4%, 37%). An exploratory analysis was also performed on the subgroup of 29 patients in SIRIUS who had an average baseline and screening blood eosinophil count <150 cells/mcL. Five (29%) patients in the group receiving NUCALA 100 mg versus 0 (0%) in the placebo group had a 90% to 100% reduction in their dose. Four (24%) patients in the group receiving NUCALA 100 mg versus 8 (67%) in the placebo group were classified as having no improvement for OCS dose.

The ACQ and SGRQ were also assessed in SIRIUS and showed results similar to those in MENSA. Lung Function Change from baseline in mean forced expiratory volume in 1 second (FEV 1 ) was measured in all 3 trials and is presented in Table 7. Compared with placebo, NUCALA 100 mg did not provide consistent improvements in mean change from baseline in FEV 1. Table 7. Change from Baseline in FEV 1 (mL) in Severe Asthma Trials FEV 1 = forced expiratory volume in 1 second, CI = confidence interval. a Dose = 75 mg intravenous. b FEV 1 at Week 52. c Dose = 100 mg subcutaneous. d FEV 1 at Week 32. Trial Difference from Placebo in Mean Change from Baseline FEV 1 (mL) (95% CI) Week 12 Week 24 Weeks 32/52 DREAM a 10 (-87, 108) 5 (-98, 108) 61 (-39, 161) b MENSA c 52 (-30, 134) 76 (-6, 159) 98 d SIRIUS c 56 (-91, 203) 114 (-42, 271) NA The effect of mepolizumab on lung function was also studied in a 12-week placebo-controlled trial enrolling patients with asthma on a moderate dose of ICS with evidence of symptoms and lung function impairment. Enrollment was not dependent on a history of exacerbations or a pre-specified eosinophil count. Change from baseline in FEV 1 at Week 12 was numerically lower in the mepolizumab treatment groups than the placebo group.

Figure 1

Chronic Rhinosinusitis with Nasal Polyps

A total of 407 adult patients with CRSwNP were evaluated in a randomized, double‑blind, placebo-controlled, multicenter, 52-week trial (NCT03085797). Patients received NUCALA 100 mg or placebo administered subcutaneously once every 4 weeks while continuing nasal corticosteroid therapy. Patients must have received background nasal corticosteroid for ≥8 weeks pre‑screening. Patients had recurrent and symptomatic CRSwNP, and had at least 1 surgery for the removal of nasal polyps within the previous 10 years.

Patients were required to have nasal obstruction symptoms with a visual analog scale (VAS) score of >5 out of a maximum score of 10. Patients were also required to have an endoscopic bilateral nasal polyp score (NPS) of ≥5 out of 8 with NPS ≥2 in each nasal cavity. Patients reported nasal obstruction VAS scores daily by placing a single mark on a continuous line labeled from 0 (none) to 100 (as bad as you can imagine). The distance along the line was converted to a 0 to 10 point scale for scoring. For NPS, polyps on each side of the nose were graded on a categorical scale (0 = no polyps, 1 = small polyps in the middle meatus not reaching below the inferior border of the middle concha, 2 = polyps reaching below the lower border of the middle turbinate, 3 = large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha, 4 = large polyps causing almost complete congestion/obstruction of the inferior meatus) for a total score of 0 to 8. Sinus CT scans were not performed at baseline nor during treatment to evaluate for sinus opacification.

The co-primary endpoints were change from baseline to Week 52 in total endoscopic NPS (0 to 8 scale) as graded by independent blinded assessors and change from baseline in nasal obstruction VAS score (0 to 10 scale) during Weeks 49 to 52. The key secondary endpoint was the time to first nasal surgery (nasal polypectomy) up to Week 52 in this trial. Other secondary endpoints were change from baseline in loss of smell VAS score during Weeks 49 to 52, and proportion of patients requiring systemic steroids for nasal polyps up to Week 52. All VAS scores were collected daily by the patients and reported on a 0 to 10 scale (0 = none, 10 = as bad as you can imagine). The demographics and baseline characteristics of patients in this trial are provided in Table 8. Table 8. Demographics and Baseline Characteristics in Chronic Rhinosinusitis with Nasal Polyps CRSwNP = chronic rhinosinusitis with nasal polyps, SD = standard deviation, OCS = oral corticosteroid, NPS = nasal polyp score, VAS = visual analog scale, CI = confidence interval, AERD = aspirin-exacerbated respiratory disease. a As graded by independent blinded assessors. N = 407 Mean age, years 49 Female, n (%) 143 White, n (%) 379 Mean CRSwNP duration in years (SD)

Patients with ≥1 surgery in past 10 years (%) 407 Patients with

≥3 surgeries in past 10 years (%) 124 OCS use (≥1 course) in past 12 months, n (%) 197 Mean bilateral endoscopic NPS a, (SD), range 0-8

Mean nasal obstruction

VAS score, (SD), range 0-10

Geometric mean blood eosinophil cells/mcL (95% CI) 390 Asthma, n (%) 289

AERD, n (%) 108 Endoscopic Nasal Polyp Score and Nasal Obstruction Visual Analog Scale Scores Patients who received NUCALA 100 mg had a statistically significant improvement (decrease) in bilateral NPS at Week 52 and nasal obstruction VAS score from Weeks 49 to 52 at the end of the 52 week treatment period ( Table 9 ). Table 9. Analyses of Endpoints in Chronic Rhinosinusitis with Nasal Polyps SD = standard deviation, SE = standard error, CI = confidence interval, NPS = nasal polyp score at Week 52. a Patients with nasal surgery were assigned worst possible score for the period after nasal surgery. Missing data were imputed based on available off-treatment data across treatment arms. Imputations were made stepwise by visit and conditioned on data from previous visits with the same covariates used in the analysis model. b Least square means from analysis using mixed model repeated measures with covariates of treatment group, geographic region, baseline score, and log(e) baseline blood eosinophil count, visit, interaction terms for visit by baseline and visit by treatment.

Scores a (range) Placebo n = 201 NUCALA 100 mg n = 206 Mean Difference vs. Placebo (95% CI) Baseline Mean (SD) Mean Change b (SE) Baseline Mean (SD) Mean Change b (SE) NPS (0-8) 5.6 0.06 5.4 -0.87 -0.93 (-1.31, -0.55) Nasal obstruction (0-10) 9.02 -2.54 8.92 -4.40 -1.86 (-2.53, -1.19) Nasal Polypectomy The key secondary endpoint was the time to first nasal surgery (nasal polypectomy) up to Week 52. The proportion of patients who had surgery was significantly reduced by 57% (hazard ratio : 0.43, 95% CI: 0.25, 0.76) in the group treated with NUCALA 100 mg compared with the placebo group ( Figure 2 ). By Week 52, 18 (9%) patients who received NUCALA 100 mg had surgery compared with 46 (23%) patients in the placebo group. Figure 2. Kaplan-Meier Plot of Time to First Nasal Surgery in Chronic Rhinosinusitis with Nasal Polyps SC = subcutaneous.

Additional Chronic Rhinosinusitis with Nasal Polyps Symptoms Scores For patients who received NUCALA 100 mg, statistically significant improvement was observed in loss of smell compared to placebo and improvements were also observed in the individual VAS symptom scores compared with patients in the placebo group in the 4-weeks prior to the end of the 52-week treatment period ( Table 10 ). Table 10: Additional Visual Analog Scale Symptom Scores Assessed at Weeks 49-52 VAS = visual analog scale, SD = standard deviation, SE = standard error, CI = confidence interval. a Patients with nasal surgery were assigned the worst possible score for the period after nasal surgery. Missing data was imputed based on available off-treatment data across treatment arms. Imputations were made stepwise by visit and conditioned on data from previous visits with the same covariates used in the analysis model. b Least square means from an analysis using mixed model repeated measures with covariates of treatment group, geographic region, baseline score, and log(e) baseline blood eosinophil count visit, interaction terms for visit by baseline and visit by treatment. c This endpoint was not prespecified in the analysis plan to adjust for multiplicity.

VAS Scores a (range) Placebo n = 201 NUCALA 100 mg n = 206 Mean Difference vs. Placebo (95% CI) Baseline Mean (SD) Mean Change b (SE) Baseline Mean (SD) Mean Change b (SE) Loss of smell (0-10) 9.68 -1.46 9.63 -2.92 -1.46 (-2.11, -0.81) Nasal discharge c (0-10) 8.78 -2.49 8.78 -4.38 -1.89 (-2.58, -1.20) Mucus in the throat c (0-10) 8.58 -2.37 8.51 -4.07 -1.70 (-2.41, -0.99) Facial pain c (0-10) 7.77 -2.04 7.76 -3.73 -1.69 (-2.43, -0.95) Corticosteroid Reduction Treatment with NUCALA 100 mg significantly reduced the need for systemic steroids for nasal polyps vs. placebo up to Week 52 (OR: 0.58, 95% CI: 0.36, 0.92). In patients who received NUCALA 100 mg, 52 (25%) required ≥1 course of systemic steroids compared with 74 (37%) in the placebo group throughout the 52-week treatment period. Results in Patients with Co-Morbid Asthma In 289 (71%) patients with co-morbid asthma, pre-specified analyses showed improvements in the co-primary endpoints consistent with those seen in the overall population in the patients who received NUCALA 100 mg compared with placebo.

Additionally, based on a post-hoc analysis in these patients, there was a greater response from baseline at Week 52 in asthma control as measured by the ACQ‑5 for NUCALA 100 mg compared with placebo (57% of the NUCALA patients met the responder threshold reduction of ≥0.5, compared to 35% in the placebo group, with an OR of 2.42 ). Figure 2

Chronic Obstructive Pulmonary Disease

The efficacy of NUCALA as add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype was evaluated in two randomized, double-blind, placebo-controlled, multicenter trials (MATINEE and METREX ). The two trials enrolled a total of 1640 adults who were randomized to receive NUCALA 100 mg or placebo administered subcutaneously every 4 weeks for a treatment duration of 52 to 104 weeks in MATINEE or 52 weeks in METREX. While 1640 adults were enrolled in the two clinical trials (MATINEE and METREX), the efficacy population consisted of 1266 adults. Both trials enrolled patients with a diagnosis of COPD with moderate to very severe airflow limitation (post-bronchodilator FEV 1 /FVC ratio <0.7 and post-bronchodilator FEV 1 of 20% to 80% predicted) and at least 2 moderate or 1 severe COPD exacerbation in the previous year despite receiving triple inhaled therapy. In MATINEE, patients were required to have a minimum blood eosinophil count of 300 cell/mcL at screening.

In METREX, there was no minimum blood eosinophil count requirement, but randomization was stratified by baseline blood eosinophil count: ≥150 cell/mcL at screening or ≥300 cell/mcL in the previous 12 months, or blood eosinophil count <150 cells/mcL at screening with no evidence of blood eosinophil count ≥300 cell/mcL in the previous 12 months. There was insufficient data from METREX to support the efficacy of NUCALA in patients with COPD with blood eosinophil count <150 cells/mcL at screening with no evidence of blood eosinophil count ≥300 cell/mcL in the previous 12 months. Thus, the efficacy population (N = 1266) included patients from MATINEE (n = 804) and patients from METREX who had a blood eosinophil count ≥150 cell/mcL at screening or ≥300 cell/mcL in the previous 12 months (n = 462). The data from this efficacy population is described below.

The demographic and baseline characteristics of MATINEE and METREX efficacy population are provided in Table 11 below. Table 11: Demographics and Baseline Characteristics of Patients with Chronic Obstructive Pulmonary Disease in MATINEE and METREX a Trials SD = standard deviation, FEV 1 = forced expiratory volume in 1 second, FVC = forced vital capacity, COPD = chronic obstructive pulmonary disease, ICS = inhaled corticosteroids, LAMA = long-acting muscarinic antagonist, LABA = long-acting beta agonist, SGRQ = St. George’s Respiratory Questionnaire, CI = confidence interval. a Patients with blood eosinophil count ≥150 cell/mcL at screening or ≥300 cell/mcL in the previous 12 months only. b Exacerbations treated with either systemic corticosteroids with or without antibiotics. c Exacerbations requiring hospitalization.

MATINEE METREX a N = 804 N = 462 Mean age (y) (SD) 66 65 Female, n (%) 253 163 White, n (%) 673 391 Asian, n (%) 112 5 Black or African American, n (%) 10 6 Other/Multiple, n (%) 9 60 Hispanic/Latino, n (%) 189 75 Current smokers, n (%) 222 134 Average smoking history (pack-years) (SD) 43 44 Post-bronchodilator % predicted FEV 1, mean (SD) 48 44 Post-bronchodilator FEV 1 /FVC, mean (SD) 0.5

Mean number of moderate b or severe c exacerbations in previous year

(SD) 2.3

Background

COPD medications at randomization: ICS/LAMA/LABA, n (%) 794 454 SGRQ score, mean (SD) 55 55 Geometric mean eosinophil count at screening, cells/mcL (95% CI) 480 260 Annualized Rate of Moderate or Severe Exacerbations in Adult Patients with Chronic Obstructive Pulmonary Disease The primary endpoint for the MATINEE and METREX trials was the annualized rate of moderate or severe exacerbations during the 52 to 104-week and 52-week treatment periods, respectively. Moderate exacerbations are defined per protocol as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined per protocol as clinically significant exacerbations that require in‑patient hospitalization (i.e., ≥24 hours) or result in death.

In both trials, NUCALA demonstrated a statistically significant reduction in the annualized rate of moderate or severe exacerbations compared with placebo when added to triple inhaled therapy (see Table 12 ). Table 12. Annualized Rate of Moderate a or Severe b Exacerbations in MATINEE and METREX Trials CI = confidence interval. a Exacerbations treated with either systemic corticosteroids/antibiotics. b Exacerbations requiring hospitalization or resulting in death. c Patients with baseline eosinophils > 150 cell/mcL at screening or ≥300 cell/mcL in the previous 12 months. MATINEE METREX c NUCALA N = 403 Placebo N = 401 NUCALA N = 233 Placebo N = 229 Exacerbation rate per year 0.80 1.01 1.40 1.71 Rate ratio vs. placebo (95% CI) 0.79 0.82 The time to first event analysis showed a statistically significant reduction in the risk of moderate or severe exacerbation for patients receiving NUCALA compared to placebo (HR: 0.77; 95% CI: 0.64, 0.93) through 104 weeks in MATINEE. NUCALA reduced the annualized rate of COPD exacerbations requiring emergency department visits and/or hospitalization when compared with placebo (rate ratio of 0.65; 95% CI: 0.43, 0.96 ) in MATINEE. Health Related Quality of Life In MATINEE and METREX, the St. George’s Respiratory Questionnaire (SGRQ) total score responder rate (defined as the proportion of subjects with SGRQ improvement from baseline of at least 4 points) at Week 52 was evaluated.

In MATINEE, the responder rate was 50% in the NUCALA group compared with 46% in the placebo group (N = 783, odds ratio : 1.17; 95% CI: 0.87, 1.57). In the METREX efficacy population, the responder rate was 42% in the NUCALA group compared to 40% in the placebo group (N = 451, odds ratio : 1.08; 95% CI: 0.74, 1.59).

Eosinophilic Granulomatosis with Polyangiitis

A total of 136 adult patients with EGPA were evaluated in a randomized, placebo-controlled, multicenter, 52-week trial (NCT02020889). Patients received 300 mg of NUCALA or placebo administered subcutaneously once every 4 weeks while continuing their stable OCS therapy. Starting at Week 4, OCS was tapered during the treatment period at the discretion of the investigator. Efficacy was assessed in this trial using co-endpoints of the total accrued duration of remission over the 52-week treatment period, defined as Birmingham Vasculitis Activity Score (BVAS) = 0 (no active vasculitis) plus prednisolone or prednisone dose less than or equal to 4 mg/day, and the proportion of patients in remission at both Week 36 and Week 48 of treatment.

The BVAS is a clinician-completed tool to assess clinically active vasculitis that would likely require treatment, after exclusion of other causes. The demographics and baseline characteristics of patients in this trial are provided in Table 13. Table 13. Demographics and Baseline Characteristics in Eosinophilic Granulomatosis with Polyangiitis EGPA = eosinophilic granulomatosis with polyangiitis, SD = standard deviation. a Prednisone or prednisolone equivalent. b e.g., azathioprine, methotrexate, mycophenolic acid. N = 136 Mean age, years

Female, n (%) 80 White, n (%) 125 Duration of

EGPA, years, mean (SD)

History of > 1 confirmed relapse in past 2 years, n (%)

100 Refractory disease, n (%) 74 Recurrence of EGPA symptoms, n (%) 68 Failed induction treatment, n (%) 6 Baseline oral corticosteroid a daily dose, mg, median (range) 12 (7.5-50) Receiving immunosuppressive therapy, b n (%) 72 Remission Patients receiving 300 mg of NUCALA achieved a significantly greater accrued time in remission compared with placebo. A significantly higher proportion of patients receiving 300 mg of NUCALA achieved remission at both Week 36 and Week 48 compared with placebo ( Table 14 ). Results of the components of remission are also shown in Table 14. In addition, significantly more patients receiving 300 mg of NUCALA achieved remission within the first 24 weeks and remained in remission for the remainder of the 52-week trial treatment period compared with placebo (19% for 300 mg of NUCALA versus 1% for placebo; OR: 19.7; 95% CI: 2.3, 167.9). Table 14. Remission and Components of Remission in Eosinophilic Granulomatosis with Polyangiitis OCS = oral corticosteroid, BVAS = Birmingham Vasculitis Activity Score, CI = confidence interval. a An odds ratio >1 favors NUCALA. Remission (OCS ≤4 mg/day + BVAS = 0) OCS ≤4 mg/day BVAS = 0 Placebo n = 68 NUCALA 300 mg n = 68 Placebo n = 68 NUCALA 300 mg n = 68 Placebo n = 68 NUCALA 300 mg n = 68 Accrued duration over 52 weeks, n (%) 0 55 32 46 27 6 3 >0 to <12 weeks 8 8 12 5 15 13 12 to <24 weeks 3 9 6 12 11 5 24 to <36 weeks 0 10 2 10 17 2 ≥36 weeks 2 9 2 14 19 45 Odds ratio (NUCALA/placebo) a 5.9 5.1 3.7 (95% CI) Proportion of patients at both Weeks 36 and 48 Patients, n (%) 2 22 7 28 23 34 Odds ratio (NUCALA/placebo) a 16.7 6.6 1.9 (95% CI) Additionally, a statistically significant benefit for these endpoints was demonstrated using remission defined as BVAS = 0 plus prednisolone/prednisone ≤7.5 mg/day. Relapse The time to first relapse (defined as worsening related to vasculitis, asthma, or sino-nasal symptoms requiring an increase in dose of corticosteroids or immunosuppressive therapy or hospitalization) was significantly longer for patients receiving 300 mg of NUCALA compared with placebo with an HR of 0.32 (95% CI: 0.21, 0.5) ( Figure 3 ). Additionally, patients receiving 300 mg of NUCALA had a reduction in rate of relapse compared with patients receiving placebo (RR: 0.50; 95% CI: 0.36, 0.70 for 300 mg of NUCALA compared with placebo). The incidence and number of relapse types (vasculitis, asthma, sino-nasal) were numerically lower with NUCALA compared with placebo.

Figure 3. Kaplan-Meier Plot of Time to First Relapse in Eosinophilic Granulomatosis with Polyangiitis SC = subcutaneous. Corticosteroid Reduction Patients receiving 300 mg of NUCALA had a significantly greater reduction in average daily OCS dose compared with patients receiving placebo during Weeks 48 to 52 ( Table 15 ). Table 15. Average Daily Oral Corticosteroid Dose during Weeks 48 to 52 in Eosinophilic Granulomatosis with Polyangiitis CI = confidence interval. a Analyzed using a proportional odds model with covariates of treatment group, baseline oral corticosteroid daily dose, baseline Birmingham Vasculitis Activity Score, and region. b An odds ratio <1 favors NUCALA. Number (%) of Patients Placebo n = 68 NUCALA 300 mg n = 68 0 2 12 >0 to ≤4.0 mg 3 18 >4.0 to ≤7.5 mg 18 10 >7.5 mg 45 28 Comparison: NUCALA/placebo a Odds ratio b 0.20 95% CI 0.09, 0.41 Asthma Control Questionnaire-6 (ACQ-6) The ACQ-6, a 6-item questionnaire completed by the patient, was developed to measure the adequacy of asthma control and change in asthma control. The on-treatment ACQ-6 responder rate during Weeks 48 to 52 (defined as a decrease in score of 0.5 or more compared with baseline) was 22% for 300 mg of NUCALA and 16% for placebo (OR: 1.56; 95% CI: 0.63, 3.88 for 300 mg of NUCALA compared with placebo). Figure 3

Hypereosinophilic Syndrome

A total of 108 adult and adolescent patients aged 12 years and older with HES for at least 6 months were evaluated in a randomized, double-blind, placebo-controlled, multicenter, 32‑week trial (NCT02836496). Patients with non-hematologic secondary HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy) or FIP1L1-PDGFRα kinase-positive HES were excluded from the trial. Patients received 300 mg of NUCALA or placebo subcutaneous once every 4 weeks while continuing their stable HES therapy. Patients entering the trial had experienced at least 2 HES flares within the past 12 months and a blood eosinophil count of 1,000 cells/mcL or higher during screening.

Historical HES flares for the trial entry criteria were defined as HES‑related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy. Patients must have been on stable HES therapy for the 4 weeks prior to randomization. HES therapy could include chronic or episodic OCS, immunosuppressive, or cytotoxic therapy.

The efficacy of NUCALA in HES was established based upon the proportion of patients who experienced a HES flare during the 32-week treatment period. A HES flare was defined as worsening of clinical signs and symptoms of HES or increasing eosinophils (on at least 2 occasions), resulting in the need to increase OCS or increase/add cytotoxic or immunosuppressive HES therapy. The demographics and baseline characteristics of patients in this trial are provided in Table 16. Table 16. Demographics and Baseline Characteristics in Hypereosinophilic Syndrome SD = standard deviation, HES = Hypereosinophilic Syndrome.

N = 108 Mean age, years (SD)

Female, n (%) 57 White, n (%) 100 Mean duration of

HES, years 5.55 Flares The trial compared the proportion of patients who experienced a HES flare or withdrew from the trial in the NUCALA and placebo treatment groups ( Table 17 ). Over the 32-week treatment period, the incidence of HES flare over the treatment period was 56% for the placebo group and 28% for the group treated with NUCALA (50% reduction). Table 17. Overview of Hypereosinophilic Syndrome Flares HES = Hypereosinophilic Syndrome, CMH = Cochran-Mantel-Haenszel, CI = confidence interval. a Analysis compared the number of patients who experienced ≥1 HES flare and/or withdrew from the trial prematurely. b An odds ratio <1 favors NUCALA. Number (%) of Patients Placebo n = 54 NUCALA 300 mg n = 54 Patients with ≥1 HES flare or who withdrew from trial 30 15 Patients with ≥1 HES flare 28 14 Patients with no HES flare who withdrew from trial 2 1 Comparison: NUCALA/placebo a CMH P value 0.002 Odds ratio b 0.28 95% CI Time to First Flare Difference was observed between NUCALA and placebo arms in the time to first HES flare ( Figure 4). The risk of first HES flare over the treatment period was 66% lower for patients treated with NUCALA compared with placebo (HR: 0.34; 95% CI 0.18, 0.67, P = 0.002). Figure 4. Kaplan-Meier Curve for Time to First Hypereosinophilic Syndrome Flare SC = subcutaneous. Proportion of Patients Who Experienced Flares during Week 20 through Week 32 From Week 20 through Week 32, significantly fewer patients experienced a HES flare or withdrew from the trial when treated with 300 mg of NUCALA compared with placebo (17% vs. 35%, respectively, P = 0.020; OR: 0.33; 95 % CI: 0.13, 0.85). Rate of Flares Patients who received NUCALA experienced significantly fewer HES flares during the 32-week treatment period compared with the placebo group ( Table 18 ). Treatment with NUCALA resulted in a statistically significant 66% reduction in the annualized rate of HES flares compared with placebo. Table 18. Frequency of Flares CI = confidence interval. a Adjusted P values based on pre-specified hierarchy of endpoints. b A rate ratio <1 favors NUCALA. Number (%) of Patients Placebo n = 54 NUCALA 300 mg n = 54 0 26 40 1 15 11 2 7 3 3 5 0 4 1 0 ≥5 0 0 Comparison: NUCALA/placebo Wilcoxon P value (unadjusted/adjusted) a 0.002/0.02 Rate/year 1.46 0.50 Rate ratio b 0.34 95% CI Brief Fatigue Inventory Brief Fatigue Inventory (BFI) Item 3 asks patients to record their worst level of weariness/tiredness severity during the past 24 hours (scale: 0 = no fatigue to 10 = as bad as you can imagine). At baseline, median BFI Item 3 scores were similar between treatment groups (4.46 for NUCALA 300 mg and 4.69 for placebo). At Week 32, BFI Item 3 scores improved with NUCALA compared with placebo ( P = 0.036). The median change from baseline score for BFI Item 3 at Week 32 was -0.66 in the group treated with NUCALA and 0.32 in the placebo group.

Figure 4

Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.

Ready to save on Nucala?

Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.

Compare Nucala Prices